Inception Sciences creates therapies with transformative potential to address diseases and disorders with significant unmet need.
Founded in 2011, Inception Sciences is a small molecule pharmaceutical incubator. Their focus is on creating high-value therapies with transformative potential to address diseases and disorders with significant unmet needs. Through partnerships with academic experts, they are translating biological insights into highly-targeted, novel drugs. Their team has a proven track record of drug discovery, having played pivotal roles in the discovery of clinical-stage compounds for the treatment of fibrosis, asthma, and COPD at Amira Pharmaceuticals, and of several high-profile drugs at Merck.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 9, 2013 | Series A | $10M | 1 | Versant Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Versant Ventures | Yes | Series A |